Related references
Note: Only part of the references are listed.Cancer Statistics, 2021
Rebecca L. Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2021)
ASA Suppresses PGE2 in Plasma and Melanocytic Nevi of Human Subjects at Increased Risk for Melanoma
Amir Varedi et al.
PHARMACEUTICALS (2020)
Immunotherapy of Melanoma: Facts and Hopes
Sarah A. Weiss et al.
CLINICAL CANCER RESEARCH (2019)
Monoclonal antibodies point to Achilles' heel in picornavirus capsid
Mihnea Bostina
PLOS BIOLOGY (2019)
Phase I Trial of an ICAM-1-Targeted Immunotherapeutic-Coxsackievirus A21 (CVA21) as an Oncolytic Agent Against Non Muscle-Invasive Bladder Cancer
Nicola E. Annels et al.
CLINICAL CANCER RESEARCH (2019)
Molecular retargeting of antibodies converts immune defense against oncolytic viruses into cancer immunotherapy
Julia Niemann et al.
NATURE COMMUNICATIONS (2019)
Plasmacytoid dendritic cells orchestrate innate and adaptive anti-tumor immunity induced by oncolytic coxsackievirus A21
Louise M. E. Mueller et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)
Mechanisms of Resistance to PD-1 and PD-L1 Blockade
Theodore S. Nowicki et al.
CANCER JOURNAL (2018)
KLRG1+ Effector CD8+ T Cells Lose KLRG1, Differentiate into All Memory T Cell Lineages, and Convey Enhanced Protective Immunity
Dietmar Herndler-Brandstetter et al.
IMMUNITY (2018)
The Current Status and Future Prospects of Oncolytic Viruses in Clinical Trials against Melanoma, Glioma, Pancreatic, and Breast Cancers
Ibrahim Ragab Eissa et al.
CANCERS (2018)
Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial
Frank Stephen Hodi et al.
LANCET ONCOLOGY (2018)
Integrating oncolytic viruses in combination cancer immunotherapy
Praveen K. Bommareddy et al.
NATURE REVIEWS IMMUNOLOGY (2018)
The YUMM lines: a series of congenic mouse melanoma cell lines with defined genetic alterations
Katrina Meeth et al.
PIGMENT CELL & MELANOMA RESEARCH (2016)
Innate Immunity Evasion by Enteroviruses: Insights into Virus-Host Interaction
Xiaobo Lei et al.
VIRUSES-BASEL (2016)
Response to Programmed Cell Death-1 Blockade in a Murine Melanoma Syngeneic Model Requires Costimulation, CD4, and CD8 T Cells
Blanca Homet Moreno et al.
CANCER IMMUNOLOGY RESEARCH (2016)
Oncolytic viruses: a new class of immunotherapy drugs
Howard L. Kaufman et al.
NATURE REVIEWS DRUG DISCOVERY (2015)
Pembrolizumab versus Ipilimumab in Advanced Melanoma
Caroline Robert et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
J. Larkin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
PD-1 blockade induces responses by inhibiting adaptive immune resistance
Paul C. Tumeh et al.
NATURE (2014)
Melanoma metastasis: new concepts and evolving paradigms
W. E. Damsky et al.
ONCOGENE (2014)
Applications of coxsackievirus A21 in oncology
Stephen Bradley et al.
ONCOLYTIC VIROTHERAPY (2014)
Oncolysis of malignant human melanoma tumors by Coxsackieviruses A13, A15 and A18
Gough G. Au et al.
VIROLOGY JOURNAL (2011)
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
F. Stephen Hodi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Mitogen-Activated Protein Kinase Inhibition Induces Translocation of Bmf to Promote Apoptosis in Melanoma
Matthew W. VanBrocklin et al.
CANCER RESEARCH (2009)
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
E. A. Eisenhauer et al.
EUROPEAN JOURNAL OF CANCER (2009)
Share Paper
